KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Receivables (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Receivables data on record, last reported at $85.0 million in Q4 2025.

  • For Q4 2025, Receivables fell 51.18% year-over-year to $85.0 million; the TTM value through Dec 2025 reached $85.0 million, down 51.18%, while the annual FY2025 figure was $85.0 million, 45.16% down from the prior year.
  • Receivables reached $85.0 million in Q4 2025 per EBS's latest filing, down from $168.8 million in the prior quarter.
  • Across five years, Receivables topped out at $341.9 million in Q2 2023 and bottomed at $81.1 million in Q2 2025.
  • Average Receivables over 5 years is $217.4 million, with a median of $211.0 million recorded in 2022.
  • Peak YoY movement for Receivables: skyrocketed 95.37% in 2023, then crashed 60.09% in 2025.
  • A 5-year view of Receivables shows it stood at $330.5 million in 2021, then tumbled by 34.52% to $216.4 million in 2022, then dropped by 10.72% to $193.2 million in 2023, then decreased by 9.89% to $174.1 million in 2024, then plummeted by 51.18% to $85.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $85.0 million in Q4 2025, $168.8 million in Q3 2025, and $81.1 million in Q2 2025.